在通用药品监管环境中使用模型综合证据的经验和观点 - - 会议报告
Eleftheria Tsakalozou1, Lanyan Fang2, Youwei Bi3
1Division of Quantitative Methods and Modeling, Office of Research and Standards (ORS), Office of Generic Drugs (OGD), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA. Eleftheria.Tsakalozou@fda.hhs.gov.
The AAPS journal
|January 10, 2024
概括
模型整合证据 (MIE) 通过告知监管决策并使有效的研究设计成为可能,帮助开发仿制药. 这种在FDA研讨会上讨论的方法简化了仿制药产品的评估,并促进了合作.
科学领域:
- 制药科学 制药科学
- 监管科学 监管科学
- 药物开发 药物开发
背景情况:
- 美国食品和药物管理局 (FDA) 公开研讨会专注于在仿制药开发中使用建模的最佳实践.
- 模型整合证据 (MIE) 越来越多地用于支持仿制药应用的监管决策.
- 讨论强调了MIE在仿制药产品评估中的演变和应用.
研究的目的:
- 总结2022年FDA关于仿制药产品开发建模研讨会的见解和讨论.
- 为了说明MIE在通用药物开发和监管决策方面的当前和潜在用途.
- 确定有助于成功的基于模型的药物开发计划的因素.
主要方法:
- 2022年FDA公开研讨会的讨论总结.
- 审查MIE在仿制药产品开发中的应用.
- 分析行业对使用建模和模拟的反.
主要成果:
- MIE方法应用于长效注射剂 (LAI) 产品,以实现高效的研究设计.
- 建模和模拟支持对局部作用和口服药物的虚拟生物可用性 (BE) 评估.
- 工业界使用MIE进行配方选择,试点研究和替代BE研究设计.
结论:
- MIE提供了重要的潜力,以告知仿制药开发和监管决策.
- 监管机构和行业之间的合作对于成功实施建模方法至关重要.
- 持续的对话可以提高对MIE在提交中的科学和监管考虑的理解.
相关概念视频
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Drug Control Governance: Regulatory Bodies and Their Impact
160
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
160
Bioequivalence: Overview
1.0K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.0K
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Drug Nomenclature
1.8K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.8K
Mechanistic Models: Overview of Compartment Models
85
Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
85


